Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Capecitabine + Oxaliplatin + Bevacizumab in mCRC
NCT00345696Phase 2Completed
- Sponsor
- Unidad Integral de Investigación en Oncología
- Start
- Jun 2006
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin, bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Unidad Integral de Investigación en Oncología. Started Jun 2006; status: completed.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00345696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00345696.